𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Efficacy of pramipexole in restless legs syndrome: A six-week, multicenter, randomized, double-blind study (effect-RLS study)

✍ Scribed by Wolfgang H. Oertel; Karin Stiasny-Kolster; Bettina Bergtholdt; Yngve Hallström; Jaan Albo; Lena Leissner; Thomas Schindler; Juergen Koester; Juergen Reess

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
109 KB
Volume
22
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

We evaluated the efficacy of pramipexole versus placebo in restless legs syndrome (RLS) for 6 weeks. Overall, 345 patients were randomly assigned in a 1:2 ratio to receive either placebo (n = 115) or pramipexole (n = 230) with a starting dose of 0.125 mg/day. The dose was individually optimized according to the Patient Global Impression (PGI) assessment, up to a maximum of 0.75 mg/day. The primary endpoint consisted of two assessments: the change from baseline in the International RLS Study Group Rating Scale (IRLS) and the proportion of patients with Clinical Global Impressions‐Improvement (CGI‐I) assessments of “much/very much improved” (CGI‐I responders) at week 6. Secondary endpoints included PGI and IRLS responder rates. Patient demographics and baseline characteristics were comparable between treatment groups. At baseline, mean IRLS scores were 24.9 (placebo) and 24.7 (pramipexole), representing severely affected patients. After 6 weeks, adjusted mean reductions (±SE) in IRLS score were 5.7 (±0.9) for placebo (median dose 0.47 mg/day) and 12.3 (±0.6) for pramipexole (median dose 0.35 mg/day; P < 0.0001). CGI‐I responder rates were 32.5% (placebo) and 62.9% (pramipexole) (P < 0.0001). For all secondary endpoints, pramipexole showed superior results. Pramipexole was well tolerated throughout the study. © 2006 Movement Disorder Society

📜 SIMILAR VOLUMES

Ropinirole is effective in the treatment
Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: A 12-week, double-blind, randomized, parallel-group, placebo-controlled study
✍ Arthur S. Walters; William G. Ondo; Tilman Dreykluft; Ron Grunstein; Daniel Lee; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB 👁 1 views

## Abstract Restless legs syndrome (RLS) is a neurological condition with significant impact on sleep and quality of life (QoL). This double‐blind, randomized, 12‐week, multinational study compared the efficacy and safety of ropinirole and placebo in RLS. In total, 267 outpatients with moderate‐to‐

A randomized, double-blind, placebo cont
A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome
✍ Ludger Grote; Lena Leissner; Jan Hedner; Jan Ulfberg 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB 👁 1 views

## Abstract Iron deficiency may exacerbate symptoms in the Restless Legs Syndrome (RLS). We investigated the effect of intravenous iron sucrose or placebo on symptoms in patients with RLS and mild to moderate iron deficit. Sixty patients with primary RLS (seven males, age 46 (9) years, S‐ferritin ≤

Systematic evaluation of augmentation du
Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom Disease): Results from a prospective, multicenter study over 66 weeks
✍ Diego García-Borreguero; Birgit Högl; Luigi Ferini-Strambi; John Winkelman; Chri 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 915 KB

## Abstract The purpose of this study was to evaluate the incidence of augmentation over 66 weeks of treatment with ropinirole in patients with primary restless legs syndrome (RLS). Augmentation is the main complication of long‐term dopaminergic treatment of RLS. Despite widespread use of ropinirol